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Introduction
During the last two decades, multiple immunotherapy-based 
strategies against cancer have been developed, with promising 
results.1 However, the efficacy of these approaches is deeply 
hampered by the tumor-intrinsic and tumor-extrinsic pathways 
that suppress effector immune responses.2 In fact, potent mech-
anisms of immunosuppression are active during tumor progres-
sion, leading to the escape of cancer cells from the immune 
system3 and limiting the effectiveness of anticancer immuno-
therapy.4 Combined immunomodulatory approaches appear 
as attractive strategies to overcome the tolerance induced by 
tumors and to tip the balance toward the generation of antitu-
mor immune responses.5 In this sense, we have previously dem-
onstrated that the sequential combination of cyclophosphamide 
(Cy) at a single low dose and sub-therapeutic doses of an ade-
novirus expressing the interleukin 12 (IL-12) gene (AdIL-12) 
mediates a potent antitumor effect against colorectal and pan-
creatic carcinomas in mice.6,7 This combined therapy induced 
complete tumor regression in > 50% of mice in a synergistic 
The use of conventional cytotoxic agents at metronomic schedules, alone or in combination with targeted agents 
or immunotherapy, is being explored as a promising anticancer strategy. We previously reported a potent antitumor 
effect of a single low-dose cyclophosphamide and interleukin-12 (IL-12) gene therapy against advanced gastrointestinal 
carcinoma, in mice. here, we assessed whether the delivery of IL-12 by gene therapy together with metronomic 
cyclophosphamide exerts antitumor effects in a murine model of colorectal carcinoma. This combination therapy was 
able, at least in part, to reverse immunosuppression, by decreasing the number of regulatory T cells (Tregs) as well as 
of splenic myeloid-derived suppressor cells (MDscs). however, metronomic cyclophosphamide plus IL-12 gene therapy 
failed to increase the number of tumor-infiltrating T lymphocytes and, more importantly, to induce a specific antitumor 
immune response. With respect to this, cyclophosphamide at a single low dose displayed a superior anticancer profile 
than the same drug given at a metronomic schedule. Our results may have important implications in the design of new 
therapeutic strategies against colorectal carcinoma using cyclophosphamide in combination with immunotherapy.
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fashion, and it significantly prolonged their survival. This strat-
egy was superior to each single treatment in reducing myeloid-
derived suppressor cells (MDSCs) and CD4+CD25+FOXP3+ 
regulatory T cells (Tregs), both in peripheral blood and in the 
spleen, as well as in increasing the number of activated den-
dritic cells (DCs) and interferon γ (IFNγ)-secreting CD4+ T 
lymphocytes.
The immunomodulatory effects of Cy have been observed not 
only when administered as a single dose but also upon metro-
nomic schedules. The expression “metronomic chemotherapy” 
(MCT) refers to the frequent administration of low doses of 
cytotoxic agents (significantly less than the maximum tolerated 
dose) over a prolonged period of time, with no or only short drug-
free intervals.8 In the past few years, this approach has attracted 
renewed interest because of its possible association with targeted 
agents or immunotherapy. Cy is the most widely-explored drug 
in MCT, both as a single agent or within combination regimens. 
Results from preclinical models indicate that metronomic Cy 
would exert anticancer effects by inhibiting angiogenesis and/or 
by stimulating the immune system.9
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Cy Mo, alone or in combination, on the prevalence of regulatory 
T cells (Tregs) by flow cytometry. We observed that untreated 
mice showed about 13% and 12% of CD4+FOXP3+ cells in the 
peripheral blood and spleen, respectively. However, mice treated 
with Cy Mo + AdIL-12 showed a significant decrease in Tregs 
levels in both compartments (3.1% and 2.1% in the peripheral 
blood and spleen, respectively; p < 0.01 vs. saline). Interestingly, 
we observed that the combination of Cy Me + AdIL-12 also 
induced a significant reduction in the levels of Tregs in peripheral 
blood (4.7%; p < 0,05 vs. saline) and spleen (3.5%; p < 0.01 vs. 
saline) (Fig. 2B and C).
It has previously been demonstrated that myeloid-derived 
suppressor cells (MDSCs) are key players in the generation of 
an immunosuppressive cancer microenvironment.11 Therefore, 
we analyzed the percentage of splenic CD11b+Gr1+ MDSCs in 
the tumor-bearing mice treated as above, and observed that both 
Cy Mo + AdIL12 and Cy Me + AdIL-12 induced a decrease in 
the levels of MDSCs in comparison with saline (4.2% and 7.6% 
respectively, vs. 16.5% in saline group; p < 0.001) 7 d after treat-
ment (Fig. 2D). However, we found that mice receiving Cy Mo 
+ AdIL-12 maintained low levels of MDSCs in comparison with 
saline- and Cy Me + AdIL12-treated animals even 15 d after ther-
apy (p < 0.001) (Fig. 2E).
Metronomic cyclophosphamide has reduced ability to 
enhance tumor immunogenicity. It has recently been reported 
that non-cytotoxic doses of some chemotherapeutic agents 
increase tumor immunogenicity, resulting in the generation of 
efficient DCs in vitro.12 In this context, we have previously dem-
onstrated that in vivo Cy Mo was able to increase the activation of 
DCs.6 Here, we decided to assess whether Cy may increase tumor 
immunogenicity in our colorectal carcinoma (CRC) model. To 
this end, tumor extracts derived from CT26-bearing mice 4 d 
after the administration of Cy Mo were used to pulsed bone mar-
row-derived DCs. As shown in Figure 3A and B, treatment with 
a single low dose of Cy in vivo (DC
CyMo
), increased allogeneic 
splenocytes proliferation (p < 0.01) and IFNγ production (p < 
0.01), as compared with no treatment (DC
Saline
). To determine 
whether these effects were due to changes in the maturation and/
or the functional status of DCs, we measured expression levels of 
Class II MHC molecules and CD80 as well as the production of 
IL-12 in CD11c+ cells derived from DCs pulsed with cancer cell 
lysates from tumor-bearing mice treated with Cy Mo (DC
CyMo
) 
or saline (DC
Saline
). Thus, DC
CyMo
 showed a higher activation 
profile (p < 0.05; Fig. 3C) and produced higher levels of IL-12 
(p < 0.05; Fig. 3D) than DC
Saline
. To explore whether Cy Me is 
also able to increase tumor immunogenicity, DCs were pulsed 
with tumor extracts obtained from CT26-bearing mice treated 
with Cy Me. As shown in Figure 3E, DCs loaded with tumor 
cell antigens from mice treated with Cy Mo induced a strong 
splenocytes proliferation rate (p < 0.05), while DCs loaded with 
tumor cell antigens from mice treated with Cy Me triggered a low 
proliferation rate, similar to that observed with DC
saline
. These 
results may reflect a reduced capacity of Cy Me to modulate the 
tumor microenvironment toward immunogenicity.
Metronomic cyclophosphamide combined with AdIL-
12 failed to generate specific antitumor CTL responses. We 
The objective of this study was to investigate the antitumor 
activity of combination regimens including cyclophosphamide-
based MCT and AdIL-12. In particular, we aimed at increasing 
the antitumor efficacy previously achieved using a single low-
dose of Cy in combination with AdIL-12 in a murine colorectal 
carcinoma model.
Results
The combination of AdIL-12 and cyclophosphamide at a single 
low dose is superior to AdIL-12 plus metronomic cyclophospha-
mide in inducing tumor regression. The aim of our first experi-
ments was to find the lowest non-toxic doses of Cy to be used 
in MCT combined with a fixed dose of AdIL-12 (109 TCID
50
, 
i.t.), which was previously used in combination with a single low 
dose of Cy (50 mg/kg, i.p.).6 We tested several doses of Cy, rang-
ing from 25 to 150 mg/kg, administered as different metronomic 
schedules (data not shown). We decided to use the metronomic 
administration of the lowest dose of Cy that displayed similar 
antitumor activities as AdIL-12 to analyze the in vivo antitumor 
effects of the combined regimen. The metronomic schedule of Cy 
25 mg/kg i.p., 3 times/week (Cy Me) was chosen. Tumor-bearing 
animals treated with a single dose of Cy (50 mg/kg) (Cy Mo) 
alone or in combination with AdIL-12 were also included in the 
study, as a comparison term.
We observed that Cy Me, Cy Mo or AdIL-12 as single agents 
induce a significant reduction in tumor burden as compared with 
control conditions (p < 0.001) and complete tumor regression 
in 5% (1/21), 7% (1/15) and 8% (1/12) of cases, respectively 
(Fig. 1A–C). Cy Mo + AdIL-12 and Cy Me + AdIL-12 also 
induced a significant inhibition of tumor growth as compared 
with control conditions (p < 0.001), but Cy Mo + AdIL-12 was 
superior than Cy Me + AdIL-12. Cy Mo + AdIL-12 induced a 
dramatic antitumor effect, leading to complete tumor eradica-
tion in 10 out of 19 mice (53%). On the contrary, Cy Me + AdIL-
12 induced complete regression in only 11% of animals (2/18) 
(Fig. 1B and C). In line with these data, the survival rate of mice 
receiving Cy Mo + AdIL-12 was significantly higher than that of 
mice treated with Cy Me + AdIL-12, Cy Me alone, Cy Mo alone, 
AdIL-12 alone or saline (p < 0.001) (Fig. 1D). Analysis of the 
in vivo interaction between each single agent in both combined 
treatments was performed by the fractional product method 
(FTV, fractional tumor volume).10 Table 1 summarizes the rela-
tive tumor volume of each experimental group, at three distinct 
time points. These results confirmed that the combination of Cy 
Me and AdIL-12 exerts less-than-additive antitumor effects.
The combination of AdIL-12 and either metronomic or sin-
gle low-dose cyclophosphamide reduced some tumor-elicited 
immunosuppressive mechanisms. We decided to investigate 
whether immunosuppressive mechanisms could be involved in 
the differential antitumoral response obtained after the admin-
istration of Cy Mo + AdIL-12 or Cy Me + AdIL-12. To this aim, 
we measured IL-10 serum levels in mice bearing CT26-derived 
tumors and receiving wither Cy Mo or Cy Mo, finding that both 
treatment schedules similarly reduced serum IL-10 (p < 0.001) 
(Fig. 2A). Then, we evaluated the effect of AdIL-12, Cy Me and 
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agent alone (p < 0.05) (Fig. 4A). On the contrary, the cytotoxic 
activity of splenocytes from animals treated with Cy Me + AdIL-
12 was similar to that observed for each individual therapy. 
Importantly, the CTL activity generated by Cy Mo + AdIL-12 
was significantly higher than that induced by Cy Me + AdIL-12 
evaluated the ability of Cy Mo + AdIL-12 and Cy Me + AdIL-12 
to generate specific cytotoxic activity against CT26 CRC cells. 
As we previously demonstrated,6 splenocytes from tumor-bearing 
mice treated with Cy Mo + AdIL-12 displayed a significantly 
higher lytic activity against CT26 cells in comparison with either 
Figure 1. (A) antitumor activity of metronomic cyclophosphamide, single low-dose cyclophosphamide, adIL-12 and their combinations in the cT26 
colorectal carcinoma model. animals were distributed into different groups: saline; metronomic cyclophosphamide (cy Me, 25 mg/kg i.p., 3 times per 
week, from day 8); single low-dose cyclophosphamide (cy Mo, 50 mg/kg i.p., day 8); adIL-12 (109 TcID50 i.t., day 9); cy Me + adIL-12 and cy Mo + adIL-12. 
Data are expressed as mean (bars = seM) tumor volume. From day 20 onward: cy Me + adIL-12 vs. cy Mo + adIL-12 p < 0.05. student’s t-test was used 
to compare tumor sizes among different groups. (B) antitumor activity of cy Me + adIL-12 and cy Mo + adIL-12; each line represents one individual 
tumor. (C) percentage of complete tumor regressions (cR). (D) animal survival analysis. Kaplan-Meier, log rank test, ***p < 0.001: saline vs. cy Me + 
adIL-12; +++p < 0.001: adIL-12 vs. cy Me + adIL-12; ##p < 0.01: cy Me vs. cy Me + adL-12; σσσp < 0.01: cy Mo + adL-12 vs. cy Me + adL-12.
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induction of antitumor immune responses against mouse CRC, 
when they are combined with an adenovirus expressing IL-12.
Although we show that of the combination of AdIL-12 and 
Cy Me inhibited CRC growth, this effect was clearly less potent 
than the response observed when AdIL-12 and Cy Mo were com-
bined. While the Cy Mo + AdIL-12 combination resulted in syn-
ergistic effects and induced complete tumor regression in more 
than 50% of mice, combination of Cy Me + AdIL-12 was less 
than additive and exerted a mild antitumor effect (2 out of 18 
complete tumor regression).
It has been widely reported that CD4+FOXP3+ Tregs facili-
tate tumor evasion20 and may hamper the success of immuno-
therapeutic strategies.21 Systemic accumulation of Tregs has 
been observed in a number of tumor models and in patients with 
poor prognosis.22-24 Taking into account our previous results, 
demonstrating the presence of active immunosuppression in the 
CT26 tumor model, which was potently inhibited by the com-
bination of AdIL-12 and Cy Mo,7 we decided to assess whether 
these tolerogenic factors were still present upon the administra-
tion of AdIL-12 + Cy Me. We found that both combined thera-
pies were able to decrease the presence of Tregs in the peripheral 
blood and spleens. In agreement with our results, Ghiringhelli et 
al. reported that metronomic cyclophosphamide leads to a selec-
tive reduction of circulating Tregs in patients with hormone-
refractory metastatic prostate cancer.25 On the other hand, we 
observed that Cy Me is able to decrease the levels of serum IL-10, 
a type Th2 cytokine involved in tumor immune escape.26,27 
These results are in agreement with our previous observations 
regarding the ability of Cy to reduce IL-10 production in differ-
ent tumor models.6,28
It is evident that both schedules of cyclophosphamide admin-
istration (Mo or Me) in combination with AdIL-12 are able to 
reduce the prevalence of relevant immunosuppressive cells as well 
as the systemic levels of IL-10. Therefore, the dissimilar antitu-
moral effect exerted on CRC by these combined therapies cannot 
be explained by a different modulation of such immunosuppres-
sive factors.
It has been observed in patients and in mice11,33 that advanced 
tumor disease is associated with increased MDSCs levels.32 
Therefore, tumor burden might affect accumulation of these 
cells. MDSCs are key players of cancer-induced immune toler-
ance and a major obstacle for cancer immunotherapy.29 Of note, 
some chemotherapeutic agents including gemcitabine and 5-fluo-
rouracil have been shown to constitute effective strategies for the 
(p < 0.05). The specificity of CTLs was confirmed with the hepa-
tocellular carcinoma BNL cell line.
Furthermore, we analyzed if the CTL activity induced by 
Cy Mo + AdIL-12 correlates with tumor-infiltrating T cells. 
Evaluation of tumor sections by immunohistochemistry revealed 
that control tumors (treated with saline) were poorly infiltrated 
by CD3+ cells (Fig. 4B) and similar results were obtained when 
CD4+ and CD8+ T cells were analyzed by flow cytometry 
(Fig. 4C and D). While both Cy Mo or Cy Me did not induce 
a significant infiltration of CD3+ T lymphocytes into the tumor, 
the administration of AdIL-12 was able to promote tumor infiltra-
tion by T cells. This CD3+ cell infiltration was greatly enhanced 
when AdIL-12 was combined with Cy Mo, but not Cy Me. This 
correlated with the amount of CD4+ and CD8+ cells detected by 
flow cytometry in tumor nodules (p < 0.05) (Fig. 4C and D).
Discussion
Cyclophosphamide is an alkylating agent that mediates DNA 
crosslinking and is widely used to treat a variety of diseases, 
including hematological and solid malignancies as well as auto-
immune disorders. Moreover, cyclophosphamide is largely uti-
lized as a conditioning regimen for bone marrow transplantation 
and stem-cell mobilization. High doses are required for direct 
effects on tumor cells, which invariably results in immunosup-
pression. In contrast, low doses of cyclophosphamide, alone or 
in combination with other immunotherapies such as cancer vac-
cines, adoptive T-cell transfer, monoclonal antibodies, exosomes 
or cytokines, have been shown to improve anticancer immune 
responses in preclinical models as well as in the clinic.9,13-15 We 
previously reported that a single low dose of cyclophosphamide 
in combination with suboptimal doses of AdIL-12 can overcome 
the tolerogenic microenvironment induced by CRC and promote 
a potent antitumor immune response in mice.6,7
More recent studies highlighted the immunostimulatory 
and/or antiangiogenic effects of the frequent and continuous 
administration of cyclophosphamide at low doses (metronomic 
regimen), opening up novel positive associations with comple-
mentary therapeutic strategies in the field of cancer immunother-
apy.16-18 In this regard, several researchers have tested metronomic 
cyclophosphamide in combination with other agents to increase 
the therapeutic efficacy.19 In this work, we decided to investigate 
whether a metronomic schedule of cyclophosphamide (Cy Me) 
could be more effective than a single low-dose (Cy Mo) in the 
Table 1. analysis of in vivo antitumor synergy by the fractional product method
Fractional tumor volume (FTV)* relative to untreated controls
CY Mo + AdIL-12 or CyMe + AdIL-12 combined treatment
Days† Cy Mo/Cy Me AdIL-12 (109 TCID50) Expected
‡ Observed R§
6 0.36/0.46 0.51 0.184/0.234 0.173/0.263 1.1/0.9
12 0.27/0.26 0.25 0.068/0.066 0.065/0.145 1.1/0.5
18 0.23/0.12 0.17 0.040/0.020 0.032/0.047 1.2/0.4
*FTV, (experimental mean tumor volume)/(control mean tumor volume). †after treatment onset. ‡cy Mo/cy Me mean FTV x (adIL-12 mean FTV).  
§R = expected FTV/Observed FTV for cy Mo + adIL-12/cy Me + adIL-12. Ratios > 1 indicate a synergistic effect, while ratios < 1 indicate a less-than-
additive effect.
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Figure 2. (A) Quantification of IL-10. serum IL-10 was measured in cT26 tumor-bearing mice treated with saline, metronomic cyclophosphamide 
(cy Me, 25 mg/kg i.p., 3 times/week, from day 8) or single low-dose cyclophosphamide (cy Mo, 50 mg/kg i.p., day 8). Data are expressed as mean 
(bars = seM) serum concentration.***p < 0.001: cy Mo vs. saline; ###p < 0.001 cy Me vs. saline. (B) percentage of cD4+FOXp3+ cells (Tregs) in peripheral 
blood. **p < 0.01: cy Mo + adIL-12 vs. saline; #p < 0.05: cy Me + adIL-12 vs. saline; (C) or spleen **p < 0.01: cy Mo + adIL-12 vs. saline; ##p < 0.01: cy Me + 
adIL-12 vs. saline. (D) percentage of splenic cD11b+Gr1+ cells at days 7 and (E) at 15 post treatment. Day 7: ***p < 0.001 cy Mo + adIL-12 vs. saline; ###cy 
Me + adIL-12 vs. saline. Day 15: ***p < 0.001 cy Mo + adIL-12 vs. saline; #p < 0.05 cy Mo + adIL-12 vs. cy Me + adIL-12. One-way aNOVa and Bonferroni 
post-test were used to compare differences among groups.
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mice, being one of the factors limiting the effectiveness of Cy Me 
+ AdIL-12-based immunotherapy in our model.
Failure of cancer immunotherapy can be due to cancer-
induced immunosuppressive mechanisms but also to the lack of 
specific T-cell responses. Since one of the main goals of immu-
notherapy is to stimulate a tumor-specific immune response, 
we evaluated whether cyclophosphamide might contribute 
to increase the immunogenicity of tumor cells and to induce 
reduction of MDSCs.30,31 In line with these observations, in the 
present study we demonstrated that, initially, the metronomic 
administration of Cy Me + AdIL-12 decreases the frequency of 
MDSCs similar than Cy Mo + AdIL-12.
However, we found that—after several weeks of administra-
tion—Cy + AdIL-12 is not as efficient as Cy Mo + AdIL-12 in 
eliminating MDSCs. These data correlated with the progressive 
increase of tumor burden observed in Cy Me + AdIL-12-treated 
Figure 3. (A) single low-dose cyclophosphamide enhances allogeneic splenocyte proliferation. splenocytes from c57BL/6 mice were stimulated in 
vitro with Dcs pulsed with tumor extracts from cT26-bearing mice treated with single low-dose cyclophosphamide (cy Mo) or saline during 5 d. cell 
proliferation was evaluated by 3h-thymidine incorporation assay. **p < 0.01: DccyMo vs. Dcsaline. (B) IFNγ quantification in supernatants from cell prolif-
eration assay. **p < 0.01: DccyMo vs. Dcsaline. (C) percentage of Mhc-II
+cD80+ cells in cD11c+ gate from pulsed DccyMo or Dcsaline. *p < 0.05: DccyMo vs. Dcsaline. 
(D) IL-12 production from pulsed DccyMo or Dcsaline. *p < 0.05: DccyMo vs. Dcsaline. (E) allogeneic splenocytes proliferation induced by both treatment with 
single low-dose or metronomic cyclophosphamide. splenocytes from c57BL/6 mice were stimulated in vitro with Dcs pulsed with tumor extracts 
obtained from cT26-bearing mice treated with cy Mo, metronomic cyclophosphamide (cy Me) or saline during 5 d. cell proliferation was evaluated as 
described above. *p < 0.05: DccyMo vs. DccyMe. Kruskal-Wallis and Dunn’s test were used to compare differences among groups.
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Increasing the frequency of circulating tumor-specific T cells 
is likely to be one important requirement for successful immu-
notherapies.37 Herein, we showed that a single dose of cyclophos-
phamide is superior than a metronomic schedule in generating a 
beneficial tumor microenvironment and improving tumor anti-
gen presentation by DCs to obtain sufficient expansion of such 
lymphocytes. Importantly, we confirmed our results by demon-
strating that Cy Mo + AdIL-12 induces a potent tumor-specific 
CTL activity while Cy Me + AdIL-12 fails to do so. In agreement 
with these observations, tumors derived from animals treated 
with Cy Mo + AdIL-12 showed an intense infiltration of CD4+ 
and CD8+ T cells, as opposed to the scarce infiltration detected 
in animals subjected to Cy Me + AdIL-12-based therapy. This 
phenomenon could be the key to achieve the therapeutic success 
observed after the use of Cy Mo + AdIL-12 and could explain, at 
least in part, the lack of response generated by the combination 
Cy Me + AdIL-12.
In summary, in this work we provide critical information to 
support the concept that Cy Mo + AdIL-12 therapy is superior 
tumor-specific CTL activity. DCs are the most potent antigen-
presenting cells and have the ability to elicit specific immune 
responses in vivo.34 It has recently been reported that low doses 
of chemotherapeutic agents can block the ability of tumor cells 
to suppress the functional activation of DCs,12 resulting in the 
generation of potent and specific CTL responses.35 Similar results 
have been reported for cyclophosphamide. In this sense, a sin-
gle dose of cyclophosphamide given to EG7 lymphoma-bearing 
mice induced the pre-apoptotic translocation of calreticulin on 
the surface of tumor cells, activating the DC antigen-processing 
machinery and inducing CD8+ T-cell cross-priming.36 We evalu-
ated whether a single low dose of cyclophosphamide might alter 
the immunogenicity of tumor cells in our CRC model. Using 
DCs pulsed with tumor cell extracts from CT26-bearing mice 
treated with cyclophosphamide, we found that single low-dose 
cyclophosphamide improves the maturation status of DCs, lead-
ing to an increased proliferation of splenocytes. On the contrary, 
metronomic cyclophosphamide failed to enhance the immuno-
genicity of tumor cells.
Figure 4. (A) single low-dose cyclophosphamide is superior to metronomic cyclophosphamide in inducing specific cTL activity. splenocytes from 
different experimental groups were stimulated in vitro with mitomycin c-treated cT26 cells for 5 d. specificity of cTL cytotoxicity was evaluated 
using BNL cells. The percentage of specific cytotoxicity was calculated according to the following formula: [(abs 492 nm experimental - abs 492 nm 
background)/(abs 492 nm maximum - abs 492 nm background)] x 100. Data represent the mean of cuatriplicate cultures. *p < 0.05: single low-dose 
cyclophosphamide (cy Mo) + adIL-12 vs. cy Mo, adIL-12 or metronomic cyclophosphamide (cy Me) + adIL-12. One way aNOVa and Tukey’s multiple 
comparison post-test was used to compare differences among groups. (B) Tumor-infiltrating T cells labeled with anti-cD3 antibodies were analyzed by 
immunohistochemistry (200×). (C) percentage of intratumoral cD4+ and (D) cD8+ cells, as analyzed by flow cytometry. *p < 0.05: cy Mo + adIL-12 vs. cy 
Me + adIL-12.
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mM KHCO
3
, 0.1 mM Na
2
-EDTA), and washed with PBS 1% 
BSA. Peripheral blood cells and splenocytes were stained with 
different conjugated-antibodies: anti-Foxp3PE (130-093-014; 
Miltenyi) and anti-CD4-PECy5 (553050; BD Biosciences), 
anti-CD11b PE (553312; BD Biosciences), anti-GR1 APC 
(551461 clone 1A8; BD Biosciences). Tumor cell suspensions 
were stained with anti-CD4 PECy5 and anti-CD8 Alexa Fluor 
488 (557668 53–67; BD Biosciences). Bone marrow-derived 
dendritic cells (DCs) gwere stained with anti-CD11c PE 
(553802 clone HL3), anti-MHC Class II FITC (553623 clone 
269) and anti-CD80 APC (560016 clone 16-10A1). Finally, 
cells were fixed with 1% paraformaldehyde and subjected to 
flow cytometry (FACS Calibur, BD Biosciences). Data were 
analyzed using WinMDI software.
Immunohistochemical analyses. Additional tumor samples 
from all experimental groups were obtained at the end of treat-
ments and fixed in 10% phosphate-buffered formalin. Five-
micrometer sections from paraffin-embedded tissues were stained 
with anti-CD3 (BD Biosciences) as published in reference 39.
Cytokine quantification. IL-10, IL-12 or IFNγ concentra-
tions were measured by specific ELISA kit (555252; 555256; 
555138, respectively; OptEIA, BD Biosciences PharMingen). 
The assays were performed according to the instructions pro-
vided by the manufacturer. Standards and samples were assayed 
in duplicates.6
DC cultures and antigen presentation assays. Bone marrow-
derived DCs from BALB/c mice were generated as described in 
reference 40, treated for 20 min with 50 mg/ml mitomycin C 
(Sigma Chemical), and washed three times with PBS. Then, DCs 
were incubated with CT26 tumor cell lysates from tumor-bearing 
mice treated with Cy, single dose or saline. As described above, 
DCs were incubated with tumor cell lysates from tumor-bearing 
mice treated with a single dose of Cy or saline. The next day, 
cell-free supernatants were collected for IL-12 quantification and 
DCs were used as stimulators in an allogeneic splenocytes prolif-
eration assay. To this end, splenocytes (1 × 106) from C57BL/6 
mice were co-cultured with DCs (1 × 105) in U-bottom 96-well 
plates and cell proliferation was evaluated after 4 d by [3H]thy-
midine incorporation assay as we describe previously in reference 
6. Also, IFNγ concentration was measured in cell-free superna-
tants as was described above. In a similar way, we investigated the 
effects of DCs pulsed with tumor cell lysates from tumor-bearing 
mice treated with Cy Me on allogeneic splenocyte proliferation. 
Each sample was assayed in cuatriplicate.
Cytotoxicity assays. Viable splenocytes (8 × 106) from all pre-
viously described experimental groups were stimulated in vitro 
with CT26 cells (previously treated with 150 μg/ml of mitomycin 
C for 30 min at 37°C; 8 × 105 cells/well in 24-well-plates) during 
5 d. Then, cells were harvested and washed three times in serum-
free medium, adjusted to 2.5 × 105/mL, and added to 96-well-
plate (effector cells). To determine specific CTL cytotoxicity, 
CT26 cells were used as target cells at 5 × 104/ml. After incuba-
tion for 4 h at 37°C, plates were centrifuged and cell-free super-
natants were obtained. Cytotoxicity was evaluated with the LDH 
Cytotoxicity Detection Kit (04744934001; Roche Diagnostics), 
following manufacturer instructions. The percentage of specific 
to Cy Me +AdIL-12 in inducing immune responses against an 
animal model of CRC. Our results may have important implica-
tions in the design of cancer immunotherapy combinations using 
cyclophosphamide as an immunomodulatory agent.
Materials and Methods
Animals and cell lines. Six- to 8-week-old male BALB/c mice 
(syngeneic with CT26) were purchased from CNEA (National 
Atomic Energy Commission, Ezeiza, Argentina) and were main-
tained at our Animal Resources Facilities (School of Biomedical 
Sciences, Austral University) in accordance with the experimen-
tal ethical committee and the NIH guidelines on the ethical 
use of animals. CT26 cells (kindly provided by Prieto MB, 
University of Navarra) were maintained in DMEM 10% FCS, 
2 mmol/L l-glutamine, 100 U/mL streptomycin and 100 mg/
mL penicillin and incubated at 37°C in a 5% CO
2
 humidified 
atmosphere.
Drugs. Cy (Filaxis) was dissolved in sterile water at a concen-
tration of 20 mg/mL and injected intraperitoneally (i.p.) at the 
indicated dose.
Adenoviral vectors. Construction AdIL-12 was previously 
described in reference 38. Briefly, recombinant adenoviruses 
were isolated from a single plaque, expanded in 293 cells and 
purified by double cesium chloride ultracentrifugation. Purified 
viruses were extensively dialyzed against 10 mmol/L Tris-1 
mmol/L MgCl
2
 and stored in aliquots at -80°C, and were care-
fully titrated by plaque assay. The concentration of recombinant 
vectors was expressed as 50% tissue culture infectious doses 
(TCID
50
) per mililiter.6
In vivo experiments. We investigated the antitumoral effects 
of Cy, in different dose and schedules of administration, in com-
bination with AdIL-12 in the CT26 colorectal carcinoma model. 
To perform in vivo experiments, CT26 cells were harvested and 
injected at a dose of 5 × 105 cells, subcutaneously, into the right 
flank of BALB/c mice (day 0). Tumors were allowed to reach 
approximately 85 mm3 in size before treatment was started. 
Animals were distributed in different treatment groups: saline 
(i.p.); single dose of Cy (Cy Mo; 50 mg/kg i.p., day 8); AdIL-
12 (109 TCID
50
 i.t., day 9); Cy Mo (50 mg/kg i.p.) + AdIL-12 
(109 TCID
50
 i.t.); metronomic dose of Cy (Cy Me; 25 mg/kg i.p., 
3 times/week, from day 8), or Cy Me (25 mg/kg i.p., 3 times/
week, from day 8) + AdIL-12 (109 TCID
50
 i.t.). Tumor growth 
was assessed twice weekly by calliper and tumor volume (mm3) 
was calculated by the formula π/6 × larger diameter × (smaller 
diameter).2 Additional experiments were performed to obtain 
peripheral blood and spleen for Tregs and myeloid-derived sup-
pressor cells quantification and tumor samples for evaluation of 
CD3, CD4 and CD8 T lymphocytes infiltration.
Flow cytometry. Seven and 15 d after treatments were 
started, animals were anesthetized and peripheral blood was 
collected by cardiac puncture and anticoagulated with EDTA. 
The mice were then sacrificed, spleens and tumors were excised, 
and single cell suspensions were prepared by mechanical dis-
ruption in phosphate buffer solution (PBS). Cell suspensions 
were treated with red blood cell lysis buffer (0.15 M NH
4
Cl, 1 
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cytotoxicity was calculated according to the following formula: 
([abs 492 nm experimental - abs 492 nm background]/[abs 492 
nm maximum - abs 492 nm background]) × 100. Data represent 
means of cuatriplicate.
Statistical analysis. Mann-Whitney’s test, Student’s t-test, 
one-way ANOVA or Kaplan-Meier log rank test (InStat, 
GraphPad Software), were used to statistically examine the dif-
ferences between groups. p values < 0.05 were considered as sta-
tistically significant.
Disclosure of Potential Conflicts of Interest
The authors declare that they have no conflict of interest.
References
1. Vanneman M, Dranoff G. Combining immunotherapy 
and targeted therapies in cancer treatment. Nat Rev 
Cancer 2012; 12:237-51; PMID:22437869; http://
dx.doi.org/10.1038/nrc3237.
2. Shapira S, Lisiansky V, Arber N, Kraus S. Targeted 
immunotherapy for colorectal cancer: monoclonal 
antibodies and immunotoxins. Expert Opin Investig 
Drugs 2010; 19:67-77; PMID:20374033; http://
dx.doi.org/10.1517/13543781003737668.
3. Croci DO, Zacarías Fluck MF, Rico MJ, Matar P, 
Rabinovich GA, Scharovsky OG. Dynamic cross-
talk between tumor and immune cells in orchestrat-
ing the immunosuppressive network at the tumor 
microenvironment. Cancer Immunol Immunother 
2007; 56:1687-700; PMID:17571260; http://dx.doi.
org/10.1007/s00262-007-0343-y.
4. Zou W. Immunosuppressive networks in the tumour 
environment and their therapeutic relevance. Nat Rev 
Cancer 2005; 5:263-74; PMID:15776005; http://
dx.doi.org/10.1038/nrc1586.
5. Melero I, Mazzolini G, Narvaiza I, Qian C, Chen 
L, Prieto J. IL-12 gene therapy for cancer: in syn-
ergy with other immunotherapies. Trends Immunol 
2001; 22:113-5; PMID:11286714; http://dx.doi.
org/10.1016/S1471-4906(00)01824-X.
6. Malvicini M, Rizzo M, Alaniz L, Piñero F, García 
M, Atorrasagasti C, et al. A novel synergistic com-
bination of cyclophosphamide and gene transfer of 
interleukin-12 eradicates colorectal carcinoma in mice. 
Clin Cancer Res 2009; 15:7256-65; PMID:19920110; 
http://dx.doi.org/10.1158/1078-0432.CCR-09-1861.
7. Malvicini M, Ingolotti M, Piccioni F, Garcia M, Bayo 
J, Atorrasagasti C, et al. Reversal of gastrointestinal 
carcinoma-induced immunosuppression and induc-
tion of antitumoural immunity by a combination 
of cyclophosphamide and gene transfer of IL-12. 
Mol Oncol 2011; 5:242-55; PMID:21515097; http://
dx.doi.org/10.1016/j.molonc.2011.03.007.
8. Kerbel RS, Kamen BA. The anti-angiogenic basis 
of metronomic chemotherapy. Nat Rev Cancer 
2004; 4:423-36; PMID:15170445; http://dx.doi.
org/10.1038/nrc1369.
9. Sistigu A, Viaud S, Chaput N, Bracci L, Proietti 
E, Zitvogel L. Immunomodulatory effects of cyclo-
phosphamide and implementations for vaccine 
design. Semin Immunopathol 2011; 33:369-83; 
PMID:21611872; http://dx.doi.org/10.1007/s00281-
011-0245-0.
10. Yokoyama Y, Dhanabal M, Griffioen AW, Sukhatme 
VP, Ramakrishnan S. Synergy between angiostatin and 
endostatin: inhibition of ovarian cancer growth. Cancer 
Res 2000; 60:2190-6; PMID:10786683.
11. Nagaraj S, Gabrilovich DI. Myeloid-derived suppres-
sor cells in human cancer. Cancer J 2010; 16:348-
53; PMID:20693846; http://dx.doi.org/10.1097/
PPO.0b013e3181eb3358.
12. Shurin GV, Tourkova IL, Kaneno R, Shurin MR. 
Chemotherapeutic agents in noncytotoxic concen-
trations increase antigen presentation by dendritic 
cells via an IL-12-dependent mechanism. J Immunol 
2009; 183:137-44; PMID:19535620; http://dx.doi.
org/10.4049/jimmunol.0900734.
13. Matar P, Rozados VR, Gervasoni SI, Scharovsky GO. 
Th2/Th1 switch induced by a single low dose of cyclo-
phosphamide in a rat metastatic lymphoma model. 
Cancer Immunol Immunother 2002; 50:588-96; 
PMID:11807622; http://dx.doi.org/10.1007/s00262-
001-0237-3.
14. Taieb J, Chaput N, Schartz N, Roux S, Novault S, 
Ménard C, et al. Chemoimmunotherapy of tumors: 
cyclophosphamide synergizes with exosome based vac-
cines. J Immunol 2006; 176:2722-9; PMID:16493027.
15. Perez EA, Suman VJ, Davidson NE, Gralow JR, 
Kaufman PA, Visscher DW, et al. Sequential versus 
concurrent trastuzumab in adjuvant chemotherapy 
for breast cancer. J Clin Oncol 2011; 29:4491-7; 
PMID:22042958; http://dx.doi.org/10.1200/
JCO.2011.36.7045.
16. Ge Y, Domschke C, Stoiber N, Schott S, Heil J, 
Rom J, et al. Metronomic cyclophosphamide treat-
ment in metastasized breast cancer patients: immuno-
logical effects and clinical outcome. Cancer Immunol 
Immunother 2012; 61:353-62; PMID:21915801; 
http://dx.doi.org/10.1007/s00262-011-1106-3.
17. Cerullo V, Diaconu I, Kangasniemi L, Rajecki M, 
Escutenaire S, Koski A, et al. Immunological effects of 
low-dose cyclophosphamide in cancer patients treated 
with oncolytic adenovirus. Mol Ther 2011; 19:1737-
46; PMID:21673660; http://dx.doi.org/10.1038/
mt.2011.113.
18. Rozados VR, Mainetti LE, Rico MJ, Zacarías Fluck 
MF, Matar P, Scharovsky OG. The immune response 
and the therapeutic effect of metronomic chemothera-
py with cyclophosphamide. Oncol Res 2010; 18:601-5; 
PMID:20939436; http://dx.doi.org/10.3727/0965040
10X12777678141662.
19. Penel N, Adenis A, Bocci G. Cyclophosphamide-
based metronomic chemotherapy: after 10 years of 
experience, where do we stand and where are we 
going? Crit Rev Oncol Hematol 2012; 82:40-50; 
PMID:21641231; http://dx.doi.org/10.1016/j.critrev-
onc.2011.04.009.
20. Nishikawa H, Sakaguchi S. Regulatory T cells in 
tumor immunity. Int J Cancer 2010; 127:759-67; 
PMID:20518016.
21. Barnett BG, Rüter J, Kryczek I, Brumlik MJ, Cheng 
PJ, Daniel BJ, et al. Regulatory T cells: a new fron-
tier in cancer immunotherapy. Adv Exp Med Biol 
2008; 622:255-60; PMID:18546633; http://dx.doi.
org/10.1007/978-0-387-68969-2_20.
22. Strauss L, Bergmann C, Szczepanski M, Gooding 
W, Johnson JT, Whiteside TL. A unique subset of 
CD4+CD25highFoxp3+ T cells secreting interleukin-10 
and transforming growth factor-beta1 mediates sup-
pression in the tumor microenvironment. Clin Cancer 
Res 2007; 13:4345-54; PMID:17671115; http://
dx.doi.org/10.1158/1078-0432.CCR-07-0472.
23. Strauss L, Bergmann C, Gooding W, Johnson JT, 
Whiteside TL. The frequency and suppressor func-
tion of CD4+CD25highFoxp3+ T cells in the circula-
tion of patients with squamous cell carcinoma of the 
head and neck. Clin Cancer Res 2007; 13:6301-11; 
PMID:17975141; http://dx.doi.org/10.1158/1078-
0432.CCR-07-1403.
24. Yaqub S, Henjum K, Mahic M, Jahnsen FL, Aandahl 
EM, Bjørnbeth BA, et al. Regulatory T cells in colorec-
tal cancer patients suppress anti-tumor immune activ-
ity in a COX-2 dependent manner. Cancer Immunol 
Immunother 2008; 57:813-21; PMID:17962941; 
http://dx.doi.org/10.1007/s00262-007-0417-x.
25. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux 
S, Martin F, et al. Metronomic cyclophosphamide 
regimen selectively depletes CD4+CD25+ regulatory T 
cells and restores T and NK effector functions in end 
stage cancer patients. Cancer Immunol Immunother 
2007; 56:641-8; PMID:16960692; http://dx.doi.
org/10.1007/s00262-006-0225-8.
26. Wittke F, Hoffmann R, Buer J, Dallmann I, 
Oevermann K, Sel S, et al. Interleukin 10 (IL-10): an 
immunosuppressive factor and independent predictor 
in patients with metastatic renal cell carcinoma. Br J 
Cancer 1999; 79:1182-4; PMID:10098756; http://
dx.doi.org/10.1038/sj.bjc.6690189.
27. Fortis C, Foppoli M, Gianotti L, Galli L, Citterio 
G, Consogno G, et al. Increased interleukin-10 
serum levels in patients with solid tumours. Cancer 
Lett 1996; 104:1-5; PMID:8640735; http://dx.doi.
org/10.1016/0304-3835(96)04213-9.
28. Matar P, Rozados VR, Gervasoni SI, Scharovsky OG. 
Downregulation of T-cell-derived IL-10 production 
by low-dose cyclophosphamide treatment in tumor-
bearing rats restores in vitro normal lymphoprolifera-
tive response. Int Immunopharmacol 2001; 1:307-19; 
PMID:11360931; http://dx.doi.org/10.1016/S1567-
5769(00)00028-X.
29. Gabrilovich DI, Nagaraj S. Myeloid-derived suppres-
sor cells as regulators of the immune system. Nat Rev 
Immunol 2009; 9:162-74; PMID:19197294; http://
dx.doi.org/10.1038/nri2506.
30. Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard 
M, Chevriaux A, et al. 5-Fluorouracil selectively 
kills tumor-associated myeloid-derived suppressor 
cells resulting in enhanced T cell-dependent anti-
tumor immunity. Cancer Res 2010; 70:3052-61; 
PMID:20388795; http://dx.doi.org/10.1158/0008-
5472.CAN-09-3690.
www.landesbioscience.com OncoImmunology 1047
39. Melero I, Gabari I, Tirapu I, Arina A, Mazzolini G, 
Baixeras E, et al. Anti-ICAM-2 monoclonal antibody 
synergizes with intratumor gene transfer of interleu-
kin-12 inhibiting activation-induced T-cell death. Clin 
Cancer Res 2003; 9:3546-54; PMID:14506140.
40. Alaniz L, Rizzo M, Malvicini M, Jaunarena J, Avella 
D, Atorrasagasti C, et al. Low molecular weight 
hyaluronan inhibits colorectal carcinoma growth 
by decreasing tumor cell proliferation and stimulat-
ing immune response. Cancer Lett 2009; 278:9-16; 
PMID:19185418; http://dx.doi.org/10.1016/j.can-
let.2008.12.029.
36. Schiavoni G, Sistigu A, Valentini M, Mattei F, Sestili 
P, Spadaro F, et al. Cyclophosphamide synergizes with 
type I interferons through systemic dendritic cell reac-
tivation and induction of immunogenic tumor apop-
tosis. Cancer Res 2011; 71:768-78; PMID:21156650; 
http://dx.doi.org/10.1158/0008-5472.CAN-10-2788.
37. van den Engel NK, Rüttinger D, Rusan M, Kammerer 
R, Zimmermann W, Hatz RA, et al. Combination 
immunotherapy and active-specific tumor cell vac-
cination augments anti-cancer immunity in a mouse 
model of gastric cancer. J Transl Med 2011; 9:140; 
PMID:21859450; http://dx.doi.org/10.1186/1479-
5876-9-140.
38. Mazzolini G, Qian C, Xie X, Sun Y, Lasarte JJ, 
Drozdzik M, et al. Regression of colon cancer and 
induction of antitumor immunity by intratumoral 
injection of adenovirus expressing interleukin-12. 
Cancer Gene Ther 1999; 6:514-22; PMID:10608348; 
http://dx.doi.org/10.1038/sj.cgt.7700072.
31. Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda 
SM. Gemcitabine selectively eliminates splenic Gr-1+/
CD11b+ myeloid suppressor cells in tumor-bearing 
animals and enhances antitumor immune activity. 
Clin Cancer Res 2005; 11:6713-21; PMID:16166452; 
http://dx.doi.org/10.1158/1078-0432.CCR-05-0883.
32. Almand B, Resser JR, Lindman B, Nadaf S, Clark 
JI, Kwon ED, et al. Clinical significance of defective 
dendritic cell differentiation in cancer. Clin Cancer Res 
2000; 6:1755-66; PMID:10815894.
33. Salvadori S, Martinelli G, Zier K. Resection of solid 
tumors reverses T cell defects and restores protec-
tive immunity. J Immunol 2000; 164:2214-20; 
PMID:10657677.
34. Shortman K, Liu YJ. Mouse and human dendritic 
cell subtypes. Nat Rev Immunol 2002; 2:151-61; 
PMID:11913066; http://dx.doi.org/10.1038/nri746.
35. Green DR, Ferguson T, Zitvogel L, Kroemer G. 
Immunogenic and tolerogenic cell death. Nat Rev 
Immunol 2009; 9:353-63; PMID:19365408; http://
dx.doi.org/10.1038/nri2545.
